Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global facial injectable market size was valued at USD 12.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2030. A growing focus on physical appearance among consumers has led to an increased demand for facial injectables in recent years. Increasing awareness regarding minimally invasive procedures due to various beauty campaigns being organized by key players in the market is also a driving factor for market growth. The ongoing COVID-19 pandemic has increased the time spent on video calls. Popularly known as the ‘Zoom Boom’, several adults are becoming more aware of their appearance. This has increased demand for cosmetic surgeries, with Botox being one of the most popular products preferred.

Patients are also opting for cosmetic surgeries owing to the ease of recovery while staying at home. Thus, the market witnessed a spike in demand during the pandemic and this trend is expected to boost further. The presence of well-established key players like Allergan; Sinclair Pharma; Galderma with comprehensive injectable fillers portfolios treating a broad range of skin indications like wrinkles, pigmentation, plumping of lips, and scars, restoring facial fullness. Furthermore, demand enhancing facial contours is also expected to drive the demand for facial injectable procedures thereby boosting market revenue. Increasing social media exposure, rising effectiveness, and approvals for facial injectables as well as the escalating desire among the global population to look aesthetically appealing and young are expected to drive the market during the forecast period.

Minimally invasive surgeries are rapidly replacing invasive surgeries. For instance, according to the American Society of plastic surgeons, nearly 18 million aesthetic treatments were undertaken by Americans in 2020. Moreover, nearly 16 million of these were done using cosmetic products, signaling an overwhelming demand for minimally invasive treatment from patients.Thus, the increasing adoption of minimally invasive surgeries, coupled with the availability of a wide range of such treatment options drives the market growth. 

According to the International Society of Aesthetic Plastic Surgery (ISAPS), the U.S. was ranked 1^st in terms of the performance of non-surgical products at a global level. Of these, injectables such as botulinum toxin and hyaluronic acid were among the most popular products. The country is backed by advanced treatment options and is home to the highest number of surgeons at a global level, with over 7,000 plastic surgeons in 2019. These factors support market growth. 

In June 2020, Allergan Aesthetics, a subsidiary of AbbVie Inc. (U.S.), received FDA approval for JUVÉDERM VOLUMA XC, for the augmentation of the chin region in adults over the age of 21. In 2019, FDA also approved, Jeuveau, which is similar to Botox, but, available at a lower cost compared to Botox. The product is found to be effective in reducing wrinkles. Signs of aging, include wrinkles and sagging of the skin due to low facial elasticity, dark spots, etc., and start appearing between 25 and 30 years of age and become more prominent from 30 to 65 years of age. Thus, the presence of a large population susceptible to various signs of aging is boosting the demand for facial injectable medicine globally.

The aesthetic industry witnessed a significant setback due to the COVID-19 pandemic in the initial quarters of 2020. However, many dermatologists reported that COVID-19 may act as a springboard that will drastically increase patient footfall post-pandemic. The survey conducted by Cynosure in June 2020 reported that the majority of the surveyed population showed a high willingness to opt for in-office non-invasive treatments. Even during the pandemic Botox and soft tissue fillers remained the most popular minimally invasive procedures in the U.S. This indicates that even though the facial injectable industry faced a slight decline in the first half of 2020, it is going to recover strongly during the forecast period. 

Product Insights

The botulinum toxin type A segment dominated the market and accounted for the largest revenue share of 49.2% in 2022. Middle-aged women are increasingly opting for fillers and injectables, including the popular, Botox to reverse the signs of aging. The Hyaluronic Acid (HA) segment is projected to witness the fastest CAGR of 9.6% during the forecast period. It is known for its ability to store moisture in the skin, thus making the skin look healthier. HA has a moisture-binding characteristic that helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin.

Cosmetic-grade HA has a low molecular weight that facilitates deep penetration of the product in the epidermis, which further helps by retaining water in cells and releases antioxidants that delay the aging process. According to the International Society of Aesthetic, around 4,053,016 procedures for hyaluronic dermal injections were performed globally in 2020.

Application Insights

The facial line correction segment dominated the market and accounted for the largest revenue share of 33.2% in 2022. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines, to name a few. Factors like growing awareness about aesthetic procedures and rising disposable income are expected to boost market growth. An increase in the use of facial injectables for parentheses lines, wrinkles on the face, lip lines, lip augmentation, lip border restoration, perioral lines, and crow’s feet lines are expected to assist in market growth.

The growing interest in physical appearance along with an increase in disposable income among the middle-class population in developing countries such as India is expected to boost demand for facial injectables for aesthetic purposes in the coming years.

The facial lift segment is expected to witness the fastest CAGR of 10.2% over the forecast period, owing to the desire for a more defined and appealing facial appearance among the global population. The convenience and safety of non-surgical procedures and the influence of social media and the beauty industry have all contributed to the rapid growth of facial contouring in the facial injectable industry. The facial lift can help individuals achieve a more defined and toned facial appearance. This technique involves the use of dermal fillers to enhance specific facial features, such as the cheekbones, jawline, and chin.

End-use Insights

The medSpa segment dominated the market and held the largest revenue share of 48.4% in 2022. It is anticipated to continue its dominance with a CAGR of 10.6% over the forecast period. The segment is projected to expand further at the fastest CAGR maintaining its dominant position over the forecast period. Medspa is a facility where cosmetic services are provided under the supervision of a licensed physician. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals.

These facilities follow all the regulatory policies and standards set by the government and have to be mandatorily owned by a physician. MedSpas are increasingly adopting novel treatment systems to gain a higher market share. The employees in medspas need to have a license in aesthetics as well as medical education.

Factors, such as membership subscriptions, service marketing, adoption of novel laser technologies, and availability of cost-effective treatments, are expected to significantly boost the growth of this segment. The Dermatology Clinics segment held the second-highest market share and is estimated to record the second-fastest CAGR from 2023 to 2030.

Regional Insights

North America dominated the facial injectable industry and accounted for the largest revenue share of more than 42.1% in 2022. This growth is owing to the large geriatric population in the U.S. and Canada. It is anticipated to propel the demand for facial injectables over the forecast period. The American Society of Plastic Surgeons (ASPS) compared the growth in rates of cosmetic surgery products from the year 2000 to 2020. It was observed that the use of Botox injections increased by 845% during this period. Thus, North America is expected to be a key revenue generator for facial injectables in the coming years.

In the Asia Pacific region, the market is projected to register the highest CAGR of 10.3% during the forecast period. The region is backed by countries such as India, Australia, and South Korea. Growing focus on physical appearances in developing countries is expected to play a key role in the demand for facial injectable treatment. India is projected to be the fastest-growing during the forecast period.

Key Companies & Market Share Insights

The key players are focusing on growth strategies, such as enhancements in existing technologies, geographical expansion, product launches, and product approvals. Recently, in February 2020, Sinclair Pharma offered distribution partnership rights of Sculptra (poly-I-Iatic acid injectable) to Galderma SA specifically in Europe. Also in 2019, one of the key players, Allergan launched a TV ad campaign for its brand, Botox Cosmetics for millennials. According to the American Academy of Facial Plastic and Reconstructive Surgery, in the past five years, Botox injections use increased by 22% among 22 to 37-year-olds. Some prominent players in the global facial injectable market include:

• Ipsen

• Merz Pharma

• Suneva Medical, Inc.

• Medytox Inc.

• Sinclair Pharma

• Bloomage BioTechnology Corporation Limited

• Anika Therapeutics Inc.

• Prollenium Medical Technologies

• Galderma

• Allergan, Inc.

Facial Injectable Market Report Scope

Global Facial Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global facial injectable market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Collagen & PMMA Microspheres

  • Hyaluronic Acid (HA)

  • Botulinum Toxin Type A

  • Calcium Hydroxylapatite (CaHA)

  • Poly-L-Lactic Acid (PLLA)

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Facial Line Correction

  • Lip Augmentation

  • Face Lift

  • Acne Scar Treatment

  • Lipoatrophy Treatment

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • MedSpa

  • Dermatology Clinics

  • Hospitals

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East And Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait